Co-Founder & Chief Scientific Officer

Chief Financial Officer

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Edgewise Therapeutics Completes Parts B and C of Phase 2 Hypertrophic Cardiomyopathy Trial

Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial

0.6666666865348816

Associate Director, Pharmaceutical Development

Edgewise Therapeutics is dedicated to discovering new medicines that enhance the lives of patients with serious muscle diseases. The Associate Director, Pharmaceutical Development will lead the end-to-end development of small molecule drug products, ensuring regulatory compliance and collaboration with internal and external stakeholders throughout the product development stages.

Associate Director, Pharmaceutical Development (EDG-2026008)

0.3333333432674408

Executive Director, Cardiovascular Clinical Development

Edgewise Therapeutics is on a mission to discover new medicines that improve the lives of patients facing serious muscle disease. The Executive Director of Cardiovascular Clinical Development will lead the strategic direction of cardiovascular programs, ensuring successful clinical development and regulatory submissions while collaborating with cross-functional teams and external stakeholders.

Executive Director, Cardiovascular Clinical Development (EDG-2025068)

Senior Manager/Associate Director, Clinical Operations

Edgewise Therapeutics is dedicated to discovering new medicines for patients with serious muscle diseases. The Senior Manager/Associate Director of Clinical Operations will provide operational expertise and strategic input for clinical trials, overseeing budgets, timelines, and vendor management to ensure successful study execution.

Senior Manager/Associate Director, Clinical Operations (EDG-2026002)

Head Of Marketing

CPP Investments Net Assets Total $777.5 Billion at Second Quarter Fiscal 2026 Français

CPP fund grew by more than $45 billion in fiscal second quarter on surging equities

Gov Tech Biz Quarterly Roundup: Q3 2025 With Jeff Cook

EQT tops €19 bln in exits, boosts cash flow amid global buyouts and fund growth

Associate Director of EDI - Community Development

Tacoma Community College (TCC) is committed to advancing equity, diversity, and inclusion within its community. The Associate Director of Equity, Diversity, and Inclusion – Community Development will lead EDI initiatives, provide educational programming, and foster collaboration among various groups to promote a culture of belonging and inclusivity on campus.

Associate Director, Pharmaceutical Development (edg 2026008)

Associate Director, Pharmaceutical Development (edg 2026008) in united states (1000+)

Associate Director, Pharmaceutical Development (EDG-2026008)

Executive Director, Cardiovascular Clinical Development (EDG-2025068)

Senior Manager/Associate Director, Clinical Operations (EDG-2026002)

Associate Director of EDI - Community Development